The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO‐94
Abstract
Aim The standard treatment for patients with clinically resectable rectal cancer is surgery. Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+). In recent years, encouraging results of pre‐operative radiotherapy have been reported. This prospective randomized phase‐III‐trial (CAO/ARO/AIO‐94) compares the efficacy of neoadjuvant RCT to standard postoperative RCT. We report on the design of the study and first results with regard to toxicity of RCT and postoperative morbidity. Patients and methods Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre or postoperative RCT: A total dose of 50.4 Gy (single dose 1.8 Gy) was applied to the tumour and the pelvic lymph nodes. 5‐FU (1000 mg/m 2/d) was administered concomitantly in the 1th and 5th week of radiation as 120 h‐continuous infusion. Four additional cycles of 5‐FU‐chemotherapy (500 mg/m 2/d, i.v.‐bolus) were applied. RCT was identical in both arms except for a small‐volume boost of 5.4 Gy postoperatively. The time interval between RCT and surgery was 4–6 weeks in both arms. Techniques of surgery were standardized and included total mesorectal excision. Primary endpoints of the study are 5‐year survival and local and distant control. Secondary endpoints include the rate of curative (R0) resection and sphincter saving procedures, toxicity of RCT, surgical complications and quality of life. Results As of July 2002, 805 patients were randomized from 26 participating institutions. Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity: The principal toxicity was diarrhea, with 12% in the postoperative RCT‐arm and 11% in the pre‐operative RCT‐arm having grade 3‐, and 1% in either arm having grade 4‐diarrhea. Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea. Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre‐op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre‐op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre‐op. RCT) from delayed wound healing. Conclusion The patient accrual to the trial is satisfactory. Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Adjuvant Therapy for Patients With Colon and Rectal Cancer
(1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450110090034 · Cited by 1,086
Cited by
A comprehensive review and update on ulcerative colitis,
Gajendran, M., Loganathan, P., Jimenez, G., Catinella, A. P., Ng, N., Umapathy, C., Ziade, N., & Hashash, J. G. (2019) · Disease-a-Month · doi:10.1016/j.disamonth.2019.02.004 · Cited by 638
Jafari, M. D., Wexner, S. D., Martz, J. E., McLemore, E. C., Margolin, D. A., Sherwinter, D. A., Lee, S. W., Senagore, A. J., Phelan, M. J., & Stamos, M. J. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2014.09.015 · Cited by 560
Scappaticci, F. A., Fehrenbacher, L., Cartwright, T., Hainsworth, J. D., Heim, W., Berlin, J., Kabbinavar, F., Novotny, W., Sarkar, S., & Hurwitz, H. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20301 · Cited by 537
Jafari, M. D., Lee, K. H., Halabi, W. J., Mills, S. D., Carmichael, J. C., Stamos, M. J., & Pigazzi, A. (2013) · Surgical Endoscopy · doi:10.1007/s00464-013-2832-8 · Cited by 337
Garcia-Aguilar, J., Shi, Q., Thomas, C. R., Chan, E., Cataldo, P., Marcet, J., Medich, D., Pigazzi, A., Oommen, S., & Posner, M. C. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1933-7 · Cited by 304
Metadata
- Authors
- Sauer, R., Fietkau, R., Wittekind, C., Rödel, C., Martus, P., Hohenberger, W., Tschmelitsch, J., Sabitzer, H., Karstens, J. ‐., Becker, H., Hess, C., Raab, R., & for the German Rectal Cancer Group
- Venue
- Colorectal Disease
- Publisher
- Wiley
- Published
- 2003-08-15
- Volume
- 5
- Issue
- 5
- Pages
- 406-415
- ISSN
- 1462-8910 (ISSN-L)
- 1463-1318
- OpenAlex
- W1990983711
- Cited by
- 219
- References
- 4
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO‐94. https://app.cochat.ai/papers/10.1046/j.1463-1318.2003.00509.x
- The paper
- Sauer, R., Fietkau, R., Wittekind, C., Rödel, C., Martus, P., Hohenberger, W., Tschmelitsch, J., Sabitzer, H., Karstens, J. ‐., Becker, H., Hess, C., Raab, R., & for the German Rectal Cancer Group. (2003). Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO‐94. Colorectal Disease. https://doi.org/10.1046/j.1463-1318.2003.00509.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.